Immunic (NASDAQ:IMUX) Releases Earnings Results, Misses Estimates By $0.37 EPS

Posted by Brenda Bartman on May 14th, 2026

Immunic (NASDAQ:IMUX – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.37), FiscalAI reports.

Immunic Price Performance

Immunic stock traded down $0.30 during trading hours on Thursday, hitting $12.65. The company had a trading volume of 159,082 shares, compared to its average volume of 338,019. The firm has a market cap of $172.26 million, a PE ratio of -1.82 and a beta of 1.20. Immunic has a one year low of $5.06 and a one year high of $15.10. The firm has a 50-day moving average of $11.39 and a 200 day moving average of $8.58.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Qube Research & Technologies Ltd bought a new position in Immunic in the 3rd quarter valued at about $29,000. Two Sigma Investments LP bought a new position in Immunic in the 3rd quarter valued at about $52,000. HB Wealth Management LLC bought a new position in Immunic in the 3rd quarter valued at about $81,000. Seven Fleet Capital Management LP bought a new position in Immunic in the 4th quarter valued at about $83,000. Finally, Virtu Financial LLC bought a new position in Immunic in the 3rd quarter valued at about $99,000. 51.82% of the stock is owned by institutional investors.

Analyst Ratings Changes

IMUX has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Immunic from a “hold” rating to a “sell” rating in a report on Sunday, April 19th. Roth Mkm reaffirmed a “buy” rating and issued a $19.00 target price on shares of Immunic in a report on Thursday. D. Boral Capital cut shares of Immunic from a “buy” rating to a “hold” rating in a report on Wednesday, April 15th. raised shares of Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd. Finally, Stifel Nicolaus set a $25.00 target price on shares of Immunic and gave the company a “buy” rating in a report on Thursday, April 16th. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Immunic has an average rating of “Buy” and a consensus target price of $50.86.

Get Our Latest Analysis on Immunic

About Immunic

(Get Free Report)

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.